Q1 2026 | Portfolio Update

Expect the Unexpected.

Supporting high-growth healthcare and enterprise technology companies with frictionless co-investment capital and unmatched ecosystem access. 

New Investments

Welcome to the Portfolio

We're proud to welcome the following companies to the JobsOhio Ventures portfolio. Each represents a bold bet on Ohio-based innovation — and on founders who are building something that matters.

Portfolio Update | Healthcare

Healthy Roster Exit

Healthy Roster, a leading provider of sports medicine and injury documentation software acquired Sway Medical, a leader in mobile concussion management, in a transaction backed by Level Equity. Together, the companies serve thousands of organizations across athletics, healthcare, and occupational health.

Portfolio Update | Healthcare

Cleveland Diagnostics: PMA Approval for IsoPSA

• This FDA Premarket Approval (PMA) now enables IsoPSA Reagent Kit© to be distributed to and run in clinical laboratories nationwide, meaning far more patients and physicians will have access to a test that helps inform patient management.
• FDA Approves IsoPSA, Cleveland Diagnostics’ Novel Blood-Based Prostate Cancer Test
  • Cleveland Diagnostics has offered IsoPSA as a Laboratory-Developed Test (LDT) since 2020. 
  • This FDA Premarket Approval (PMA) now enables IsoPSA Reagent Kit© to be distributed to and run in clinical laboratories nationwide, meaning far more patients and physicians will have access to a test that helps inform patient management.
  • Medicare and a growing number of commercial payors now cover the test. IsoPSA is included in leading clinical practice guidelines, including the National Comprehensive Cancer Network (NCCN) Prostate Cancer Early Detection Guideline (2025) and the Early Detection of Prostate Cancer: American Urology Association/Society of Urologic Oncology Guideline (2023).

Portfolio Update | Deep Tech

Niobium Secures $23M+ Oversubscribed Financing to Lead FHE Hardware Acceleration for the Quantum and AI Era

Niobium's FHE hardware accelerator enables computing on encrypted data, providing a mathematical guarantee of data privacy. The investment marks growing market conviction that FHE will play a foundational role in securing the data economy as AI, blockchain, and quantum computing reshape how organizations manage privacy and trust.

The round includes returning investors such as Fusion Fund and new investors including Blockchange Ventures and ADVentures (the corporate venture arm of Analog Devices, Inc.)

Portfolio Update | Healthcare

Clarametyx Biosciences Announces Positive Topline Data from Phase 2a Study Evaluating CMTX-101 in Cystic Fibrosis

• Study met its primary endpoint demonstrating safety and tolerability of CMTX-101 in people with cystic fibrosis
• CMTX-101 treatment produced clinically meaningful reductions in key inflammatory biomarkers and pulmonary Pseudomonas aeruginosa burden, and preservation of pulmonary function

Portfolio Update | Deep Tech

Afference raised $15M Series A

Founder Spotlight

In Their
Own Words

Born from three decades of neural interface research at Case Western Reserve University, Afference represents a perfect fusion of deep scientific expertise and commercial innovation. Dr. Dustin Tyler, who spent years developing technology to help patients with limb loss regain sensation, partnered with entrepreneur Jacob Segil to translate this medical breakthrough into a consumer technology that could transform virtual and augmented reality experiences.